Healthcare Wrap: Genetic Signatures and Immutep lead a week of sharp moves

Genetic Signatures (ASX:GSS) topped the healthcare board with a 106.25% weekly jump after it secured a 10-year supply deal with Denmark’s Hvidovre Hospital for gastrointestinal testing. Investors cared because the contract is long, starts with 28,000 tests in year one and grows from there. Immutep (ASX:IMM) followed with a 72.50% rise after US regulators granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. In plain English, that status can give a drug maker fee reductions and up to seven years of market exclusivity if the drug later wins approval. Orthocell (ASX:OCC) gained 26.22% as approval to sell Remplir™ into 221 US military and veterans hospitals quickly turned into its first surgery inside that network.

Contracts drove the biggest re-rating

The strongest buying came where revenue looked easier to picture. PainChek (ASX:PCK) climbed 20.00% after striking a deal with Sabra Health Care REIT that could place its pain assessment software across as many as 20,000 North American beds. Sabra is set to fund deployment, which matters because it lowers the burden on operators to sign up. Pro Medicus (ASX:PME) added 17.19% on a A$37 million renewal with Northwestern Medicine. That contract also includes higher minimum usage and higher fees, so investors could see why the value increased. Memphasys (ASX:MEM), by contrast, fell 16.67% even after reporting record quarterly revenue and A$1.4 million in multi-year contracts. The likely problem was scale. Sales improved, but cash runway remained under two quarters, which means investors may still be worried about another funding round.

Cancer drug and imaging names stayed active

Radiopharma was busy again. Telix Pharmaceuticals (ASX:TLX) unveiled a partnership with Regeneron that includes a US$40 million upfront payment and possible milestones above US$2 billion. It also launched US$550 million of convertible bonds to refinance existing debt and fund growth. A convertible bond is debt that can later turn into shares. Investors often like the lower interest cost, but they also weigh future dilution and the mechanics of hedge trading around the issue. In Telix’s case, the stock reopened at a big gap and then slid 8.10%, so early gains evaporated. Clarity Pharmaceuticals (ASX:CU6) eased 1.57% despite locking in enough US manufacturing to produce up to 600,000 doses a year of its prostate cancer imaging agent. Radiopharm Theranostics (ASX:RAD) fell 6.82% after finishing enrolment in a phase 2b imaging trial, even with interim data showing 90% agreement with MRI scans. That sort of move often means investors want final data, not just progress updates.

US hospital access remained a powerful trigger

Orthocell’s week showed why commercial access matters. First, it won approval for Remplir™ across the US Department of Defense and Veterans Affairs network. Then it reported the first surgery in that system. That sequence matters because approval alone does not prove doctors will use a product. AVITA Medical (ASX:AVH) also rose 6.54% after interim study results showed its wound product cut average time to skin grafting from 33.2 days to 13.6 days. EMVision (ASX:EMV) gained 9.00% as recruitment expanded across eight hospitals in its key US stroke trial, while cash reached $18.4 million. For beginners, cash matters because medical device trials are expensive and delays are common.

Fresh cash helped some stocks and hurt others

Capital raisings produced mixed reactions. BlinkLab (ASX:BB1) slipped 1.23% after a A$17.5 million placement to fund autism and ADHD diagnostic programs, and the stock sat below its reopening level. Oneview Healthcare (ASX:ONE) fell 7.69% after its security purchase plan raised only A$0.3 million against a A$2 million target, forcing the final A$7 million placement tranche into a later shareholder vote. Percheron Therapeutics (ASX:PER) dropped 20.00% despite closing a A$2.2 million entitlement offer, which suggests investors saw the raise as necessary but not enough to change the near-term story. Neurizon (ASX:NUZ) did better, rising 3.01% after lifting total proceeds to about A$8.5 million for its ALS program.

Healthcare services and smaller commercial names added another layer

Monash IVF (ASX:MVF) rose 15.04% after receiving a sweeter A$0.90 per share proposal from the Genesis Capital and WHSP consortium. Still, the shares gave back some ground after reopening, which tells you investors are not treating the bid as certain. Immuron (ASX:IMC) gained 29.63% on 16% quarterly sales growth for Travelan. Audeara (ASX:AUA) had two pieces of news: a new assistive listening deal for Australian schoolchildren and a second straight quarter of positive operating cash flow. Yet the stock finished the week down 8.20%, even though it traded above its reopening level later on. Noxopharm (ASX:NOX) added 17.19% across a CEO handover from the outgoing chief executive to the chief scientific officer. Investors appeared comfortable because the company paired the management change with a clear plan to push its Sofra platform further.